Allergology International

Allergology International

Volume 71, Issue 4, October 2022, Pages 472-480
Allergology International

Invited Review Article
Executive summary: Japanese pediatric guideline for the treatment and management of asthma (JPGL) 2020

https://doi.org/10.1016/j.alit.2022.07.007Get rights and content
Under a Creative Commons license
open access

Abstract

This article covers the salient and updated themes of the Japanese Pediatric Guidelines for the Treatment and Management of Asthma (JPGL) 2020 published by the Japanese Society of Pediatric Allergy and Clinical Immunology. In the 2020 guidelines, five new clinical questions (CQs) have been added to address the 12 CQs regarding the treatment of childhood asthma. “Infant and preschool asthma” is diagnosed when young children (<6 years of age) have three or more episodes of clear expiratory wheezing, which continue for more than 24 h, and symptom improvement can be observed after beta-2 agonist inhalation. In children without clear improvement, diagnostic therapeutic trial for the duration of 1 month with controller treatment can be used. Since long-term management is initiated, the treatment level is adjusted based on the current control status and the management of risk factors, with the provision for holistic care. This underscores the smooth transition of pediatric patients into adult services. There are several differences between the JPGL and the guidelines of other countries. Further evidence is obtained as the utility of the newly proposed management plans should be evaluated in the Japanese population.

Keywords

Allergy
Childhood asthma
Clinical questions
GRADE
Guidelines

Cited by (0)

Peer review under responsibility of Japanese Society of Allergology.

1

The members of the Committee for Japanese Pediatric Guideline for the Treatment and Management of Asthma are listed in Acknowledgements section.